Related Experiment Video

Updated: May 12, 2026

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion
09:23

Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion

Published on: October 20, 2016

13.9K

Ara-C suppresses H3 K27-altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade

Bo Pang1,2, Yilin Wu1, SongYuan An1,2

  • 1Department of Molecular Neuropathology, Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.

Science Advances
|April 16, 2025
PubMed

Insights

Cytarabine (Ara-C) effectively inhibits H3 K27-altered spinal cord diffuse midline glioma (H3-SCDMG) proliferation and shows promise in clinical trials. Combining Ara-C with immunotherapy may enhance antitumor responses against this challenging cancer.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Cancer Therapeutics

Background:

  • H3 K27-altered spinal cord diffuse midline glioma (H3-SCDMG) presents significant therapeutic challenges due to its aggressive nature.
  • Analysis of clinical samples reveals heightened tumor cell proliferation in H3-SCDMG, indicating potential therapeutic vulnerabilities.

Purpose of the Study:

  • To identify effective therapeutic agents for H3-SCDMG.
  • To investigate the mechanisms of action for promising drugs.
  • To explore combination strategies involving immunotherapy.

Main Methods:

  • Drug screening on H3 K27M cell models, patient-derived cells, and xenografts.
  • Mechanistic studies assessing DNA damage, cell-cycle arrest, and apoptosis.
  • Investigator-initiated clinical trial and analysis of immune cell infiltration and immune checkpoint ligand expression.

Main Results:

  • Cytarabine (Ara-C) demonstrated high efficacy in inhibiting H3-SCDMG proliferation across multiple models.
  • Ara-C suppressed tumor growth via DNA damage, cell-cycle arrest, and apoptosis.
  • Clinical trial showed benefits in 3 out of 4 patients; Ara-C treatment induced senescence and immune cell infiltration, with upregulation of immune checkpoint ligands.

Conclusions:

  • Ara-C shows potential as a monotherapy for H3-SCDMG.
  • Combination therapy with Ara-C and dual PD-1/TIGIT blockade is a promising strategy to overcome immune evasion.
  • These findings offer novel therapeutic avenues for managing H3-SCDMG.

More Related Videos

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.0K
Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

837

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.